Ameriprise Financial Inc. Lowers Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Ameriprise Financial Inc. trimmed its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 12.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,123 shares of the company’s stock after selling 9,169 shares during the quarter. Ameriprise Financial Inc.’s holdings in Takeda Pharmaceutical were worth $862,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after buying an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $52,000. Cromwell Holdings LLC bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth approximately $61,000. Venturi Wealth Management LLC increased its position in shares of Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock worth $67,000 after purchasing an additional 4,260 shares during the last quarter. Finally, Lindbrook Capital LLC increased its position in shares of Takeda Pharmaceutical by 65.0% in the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company’s stock worth $68,000 after purchasing an additional 2,029 shares during the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 0.2%

Shares of NYSE TAK opened at $15.07 on Tuesday. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm’s 50 day simple moving average is $14.66 and its two-hundred day simple moving average is $14.06. The stock has a market capitalization of $47.94 billion, a P/E ratio of 37.66, a PEG ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The business had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. As a group, analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.